Breaking Finance News

Wells Fargo announced Quest Diagnostics (NYSE:DGX), bumping up its stock price target to $88.00 today

Yesterday Quest Diagnostics (NYSE:DGX) traded 0.08% higher at $91.59. DGX’s 50-day average is $101.06 and its two hundred day average is $104.89. With the last stock price close down -12.74% relative to the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the date range. Volume of trade was up over the average, with 1,615,029 shares of DGX changing hands over the typical 1,045,730

In a report released on 10/12/2017 Wells Fargo increased the stock price target of Quest Diagnostics (NYSE:DGX) to $88.00 indicating a possible downside of -0.04%.

Performance Chart

Quest Diagnostics (NYSE:DGX)

With a total market value of $0, Quest Diagnostics has price-earnings ratio of 18.44 with a one year low of $79.12 and a one year high of $112.96 .

A total of 16 equity analysts have released a ratings update on DGX. One equity analyst rating the company a strong buy, two brokerages rating the company a buy, seventeen brokerages rating the company a hold, two brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $74.13.

General Company Details For Quest Diagnostics (NYSE:DGX)

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs). Its Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers, and its healthcare information technology businesses, which offers solutions for healthcare providers. The Company's services are provided under the Quest Diagnostics brand, but it also provides services under other brands, including AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Quanum and Care360.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *